Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells
Authors:
Open Access
- 2 September 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (9) , e0256755
Abstract
Background and aim: As a multiple tyrosine kinase inhibitor, sorafenib is widely used to treat hepatocellular carcinoma (HCC), but patients frequently face resistance problems. Because the mechanism controlling sorafenib-resistance is not well understood, this study focused on the connection between tumor characteristics and the Nrf2 signaling pathway in a sorafenib-resistant HCC cell line. Methods: A sorafenib-resistant HCC cell line (Huh7) was developed by increasing the dose of sorafenib in the culture medium until the target concentration was reached. Cell morphology, migration/invasion rates, and expression of stemness-related and ATP-binding cassette (ABC) transporter genes were compared between sorafenib-resistant Huh7 cells and parental Huh7 cells. Next, a small interfering RNA was used to knock down Nrf2 expression in sorafenib-resistant Huh7 cells, after which cell viability, stemness, migration, and ABC transporter gene expression were examined again. Results: Proliferation, migration, and invasion rates of sorafenib-resistant Huh7 cells were significantly increased relative to the parental cells with or without sorafenib added to the medium. The expression levels of stemness markers and ABC transporter genes were up-regulated in sorafenib-resistant cells. After Nrf2 was knocked down in sorafenib-resistant cells, cell migration and invasion rates were reduced, and expression levels of stemness markers and ABC transporter genes were reduced. Conclusion: Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant HCC cells.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP19fk0210048 and JP20fk0210048)
- Grant-in-Aid for Scientific Research (B) (18K02871)
This publication has 35 references indexed in Scilit:
- EpCAM-regulated intramembrane proteolysis induces a cancer stem cell-like gene signature in hepatitis B virus-infected hepatocytesJournal of Hepatology, 2016
- Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5+ liver cancer initiating cells by suppressing negative regulators of β-catenin signalingOncogene, 2015
- Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targetsNature Genetics, 2015
- Toward clinical application of the Keap1–Nrf2 pathwayTrends in Pharmacological Sciences, 2013
- Cancer Chemoprevention Mechanisms Mediated Through the Keap1–Nrf2 PathwayAntioxidants & Redox Signaling, 2010
- Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and TherapyAnnual Review of Medicine, 2010
- EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell FeaturesGastroenterology, 2009
- Transcriptome classification of HCC is related to gene alterations and to new therapeutic targetsHepatology, 2006
- Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5Cancer Research, 2006
- Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region.Proceedings of the National Academy of Sciences, 1994